Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes

Mbawuike, Innocent N.; Wyde, Philip R.; Anderson, Peter M.

doi:10.1016/0264-410x(90)90093-2

Cited by 85 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16,17,57 In the present study, the frequency of memory CD8 + T cells following in vitro influenza virus stimulation was demonstrated to be significantly lower in aged mice in comparison to young mice. In addition, influenza virus-specific CD8 + T cells from old mice exhibited significantly increased apoptosis as indicated by elevated Annexin V binding and increased expression of the cell death signaling molecules, Fas, FasL, TFN-a and TNFRI as determined by flow cytometric analysis.…”

Section: Discussionmentioning

confidence: 84%

Apoptosis and reduced influenza A virus specific CD8+ T cells in aging mice

et al. 2002

View full text Add to dashboard Cite

Some studies have reported increased apoptosis in CD8 + T cells from aged mice. We previously demonstrated diminished virus-specific CD8 + cytotoxic T lymphocyte (CTL) activity in aged mice in comparison to young mice. The present study investigated the role of apoptosis in age-related influenza virus-specific CD8 + CTL deficiency. Splenocytes from influenza-primed aged and young mice were stimulated in vitro with virus. The CD8 + T cell/total lymphocyte ratios correlated with CTL activity and were significantly decreased and increased in aged and young mice, respectively. Fas, FasL, TNF-a and TNFR-p55 expression, measured by flow cytometry, ELISA and/or RT ± PCR, were significantly elevated in aged mice. Apoptotic CD8 + T cells (Annexin V binding) were also elevated in aged mice. IL-12 treatment increased CD8 + CTL activity and IFN-g production but did not affect apoptosis. Thus, apoptosis may contribute to reduced influenza virusspecific CD8 + T cell frequency, CTL deficiency and increased influenza disease in aging.

show abstract

Section: Discussionmentioning

confidence: 84%

Apoptosis and reduced influenza A virus specific CD8+ T cells in aging mice

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Virulent challenge pools of mouse-adapted influenza viruses A/Hong Kong/1/68 (A/H3N2) and A/Taiwan/1/86 (A/H1N1) viruses were prepared by serially passaging each virus in mice as described previously [18-20]. The NP of A/HK/68 and A/Taiwan/1/86 viruses are antigenically similar to each other and to A/PR/8/34 (H1N1) virus NP while the HA and NA surface glycoproteins of A/HK/68 and A/Taiwan/86 are antigenically distinct.…”

Section: Methodsmentioning

confidence: 99%

Control of mucosal virus infection by influenza nucleoprotein-specific CD8+ cytotoxic T lymphocytes

2007

View full text Add to dashboard Cite

Background: MHC class I-restricted CD8 + cytotoxic T lymphocytes (CTL) are thought to play a major role in clearing virus and promoting recovery from influenza infection and disease. This has been demonstrated for clearance of influenza virus from the lungs of infected mice. However, human influenza infection is primarily a respiratory mucosal infection involving the nasopharynx and tracheobronchial tree. The role of CD8 + CTL directed toward the influenza nucleoprotein (NP) in defense against influenza virus infection at the respiratory mucosa was evaluated in two separate adoptive transfer experiments.

show abstract

“…More than 300 synthetic derivatives of muramyl dipeptide have been produced in the search for molecules that retain their adjuvant activity yet in newborns (6), aged (7) and immunocompromised hosts (8). Adjuvants can also promote T-cell proliferation and cellmediated immunity (9).…”

Section: Contextmentioning

confidence: 99%

Vaccine Adjuvants: The Current Necessity of Life

Gupta

Chaphalkar

2015

Shiraz E-Med J

View full text Add to dashboard Cite

Context:Vaccination is considered as the most cost effective method for the prevention of human diseases. For this prevention method, we need certain substances to increase or boost the antibody as well as cell-mediated immune response against various bacterial as well as viral pathogens. Until now, alum was considered as the safest adjuvant for human use, licensed by the United States Food and Drug Administration. Due to the poor adjuvanticity of alum, conventional vaccines require multiple recall injections, at different time intervals, to attain or sustain the optimal immune response. The present review discusses about the necessity of adjuvants for vaccines. Evidence Acquisition: A number of factors such as slow release of antigen (depot effect), more efficient delivery of antigen to draining lymph nodes, non-specific activation of antigen-presenting cells or of B and/or T-lymphocytes, increased uptake of antigen by antigenpresenting cells or increased recruitment of immune cells to the site where the antigen is present, can contribute to increased immune responses to immunization. Many of these factors involve the interaction of various immune system components and specific anatomical features, making them difficult to replicate in model systems in vitro. Results: Despite the development of many potent adjuvant formulations with vaccine antigen during the last 80 -90 years, aluminum compounds are still the only approved adjuvants used for routine human vaccines. Conclusions: Based on pre-clinical and preliminary clinical observations, it appears that the range of adjuvants accepted for human vaccines will expand in the coming years.

show abstract

Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes

Cited by 85 publications

References 30 publications

Apoptosis and reduced influenza A virus specific CD8+ T cells in aging mice

Apoptosis and reduced influenza A virus specific CD8+ T cells in aging mice

Control of mucosal virus infection by influenza nucleoprotein-specific CD8+ cytotoxic T lymphocytes

Vaccine Adjuvants: The Current Necessity of Life

Contact Info

Product

Resources

About